Omalizumab for the treatment of solar urticaria: Case series and systematic review of the literature
The Journal of Allergy and Clinical Immunology: In Practice | Mar 24, 2018
Snast I, et al. - Omalizumab was tested as a treatment option for patients with solar urticaria (SU). Clinical benefits of omalizumab were seen in approximately 80% of SU patients. Higher monthly dosages of omalizumab may benefit those failing to improve on standard doses.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
